Outstanding principal and accrued interest.

No definition available.

Name:	rfl_OutstandingPrincipalAndAccruedInterest
Namespace Prefix:	rfl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 310
-SubTopic 20
-Name Accounting Standards Codification
-Section 40
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481628/310-20-40-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-2

+ Details

Name:	us-gaap_AccountsNotesAndLoansReceivableLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Face amount or stated value per share of common stock.

+ References

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:	us-gaap_ConvertibleDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-4

+ Details

Name:	us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

+ Details

Name:	us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

+ Details

Name:	us-gaap_DebtInstrumentMaturityDate
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Purchase price of common stock expressed as a percentage of its fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-4

+ Details

Name:	us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

Convertible Notes Receivable, Due from Cyclo Therapeutics, LLC. (Details) - USD ($) $ / shares in Units, $ in Millions													12 Months Ended
	Mar. 06, 2025	Feb. 04, 2025	Jan. 03, 2025	Dec. 23, 2024	Dec. 21, 2024	Dec. 05, 2024	Nov. 07, 2024	Oct. 08, 2024	Sep. 09, 2024	Aug. 21, 2024	Jul. 16, 2024	Jun. 11, 2024	Jul. 31, 2025	Mar. 25, 2025
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Outstanding principal and accrued interest				$ 2.5									$ 30.6
Common stock, shares issued (in Shares)				3,968,254										12,998,194
Common stock, par value (in Dollars per share)				$ 0.63
Cyclo Convertible Note I [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Principal amount												$ 2.0
Notes received in cash												$ 2.0
Maturity date												Mar. 31, 2025
Interest rate												5.00%
Cyclo Convertible Note II [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Principal amount											$ 2.0
Notes received in cash											$ 2.0
Maturity date											Mar. 31, 2025
Interest rate											5.00%
Cyclo Convertible Note III [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Principal amount										$ 3.0
Notes received in cash										$ 3.0
Maturity date										Mar. 31, 2025
Interest rate										5.00%
Common stock, percentage										49.90%
Cyclo Convertible Note IV [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Principal amount									$ 3.0
Notes received in cash									$ 3.0
Maturity date									Mar. 31, 2025
Interest rate									5.00%
Cyclo Convertible Note [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Maturity date					Feb. 15, 2025
Common stock, percentage	49.90%	49.90%	49.90%			49.90%	49.90%	49.90%	49.90%
Cyclo Convertible Note V [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Principal amount								$ 3.0
Notes received in cash								$ 3.0
Maturity date								Mar. 31, 2025
Interest rate								5.00%
Cyclo Convertible Note VI [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Principal amount							$ 2.0
Notes received in cash							$ 2.0
Maturity date							Mar. 31, 2025
Interest rate							5.00%
Cyclo Convertible Note VII [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Principal amount						$ 1.0
Notes received in cash						$ 1.0
Maturity date						Mar. 31, 2025
Interest rate						5.00%
Cyclo Convertible Note VIII [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Principal amount			$ 3.0
Notes received in cash			$ 3.0
Maturity date			Mar. 31, 2025
Interest rate			5.00%
Cyclo Convertible Note IX [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Principal amount		$ 2.0
Notes received in cash		$ 2.0
Maturity date		Mar. 31, 2025
Interest rate		5.00%
Cyclo Convertible Note X [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Principal amount	$ 2.5
Notes received in cash	$ 2.5
Maturity date	Mar. 31, 2025
Interest rate	5.00%
Note Purchase Agreement [Member] \| Cyclo Convertible Note I [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Maturity date												Nov. 11, 2024
First Amended and Restated Note Purchase Agreement [Member] \| Cyclo Convertible Note II [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Maturity date											Nov. 11, 2024
Second Amended and Restated Note Purchase Agreement [Member] \| Cyclo Convertible Note III [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Maturity date										Dec. 21, 2024
Third Amended and Restated Note Purchase Agreement [Member] \| Cyclo Convertible Note IV [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Maturity date									Dec. 21, 2024
Fourth Amended and Restated Note Purchase Agreement [Member] \| Cyclo Convertible Note V [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Maturity date								Dec. 21, 2024
Fifth Amended and Restated Note Purchase Agreement [Member] \| Cyclo Convertible Note VI [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Maturity date							Dec. 21, 2024
Sixth Amended and Restated Note Purchase Agreement [Member] \| Cyclo Convertible Note VII [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Maturity date						Dec. 21, 2024
Seventh Amended and Restated Note Purchase Agreement [Member] \| Cyclo Convertible Note VIII [Member]
Convertible Note Receivables, Due From Cyclo Therapeutics, Inc. [Line Items]
Maturity date			Feb. 15, 2025